E board review in Breast Cancer February 2008 Word from Editor

November 26th 2024

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Tanios S. Bekaii-Saab, MD, FACP

Bridging Racial and Ethnic Minority Disparities in Pancreatic Cyst Surveillance

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

Russell C. Langan, MD

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Andrew M. Evens, DO, MS

November 18th 2024

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

American Society for Transplantation and Cellular Therapy

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.

Onvansertib Combo Shows Significant Efficacy in KRAS+ Colorectal Cancer

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

Related Content

November 26th 2024

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

Tanios S. Bekaii-Saab, MD, FACP

Bridging Racial and Ethnic Minority Disparities in Pancreatic Cyst Surveillance

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Russell C. Langan, MD

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

Andrew M. Evens, DO, MS

November 18th 2024

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

American Society for Transplantation and Cellular Therapy

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.